L Pfeifer 1 , D Strobel 1 , M F Neurath 1 , D Wildner 1 Show Affiliations »
Abstract
PURPOSE: To explore the impact of cholestasis on liver stiffness assessed by acoustic radiation force impulse (ARFI) technology. MATERIALS AND METHODS: Over a period of four months, patients with sonographic cholestasis and increased cholestatic blood values (Bilirubin, γGT, AP > 2 times ULN) scheduled for endoscopic therapy were recruited. Exclusion criteria were: known liver disease; signs of cirrhosis at ultrasound (irregular liver veins and/or surface); heart insufficiency (NYHA III-VI). ARFI (Siemens S2000), ultrasound and blood examinations were performed before and in a subgroup after successful biliary drainage. RESULTS: In total, 21 patients with cholestasis were included in the study. ARFI measurements were above the cut-off for cirrhosis (1.8 m/s) in all patients with a mean of 2.91 m/s ± 0.89 m/s without a history or signs of cirrhosis. Bilirubin, γGT and AP were elevated on average to 9.7 ± 5.3 mg/dl, 1192 ± 960 U/l and 730 ± 389 U/l. A subgroup of 10 patients was measured after successful drainage. ARFI measurements declined in all patients of that subgroup on average by 0.76 m/s at a mean time interval of 4.5 days (p < 0.001). CONCLUSION: Cholestasis significantly increases liver stiffness assessed by ARFI. Therefore, it is important to exclude profound cholestasis when using ARFI for evaluating patients for liver fibrosis. © Georg Thieme Verlag KG Stuttgart · New York.
PURPOSE: To explore the impact of cholestasis on liver stiffness assessed by acoustic radiation force impulse (ARFI) technology. MATERIALS AND METHODS: Over a period of four months, patients with sonographic cholestasis and increased cholestatic blood values (Bilirubin , γGT, AP > 2 times ULN) scheduled for endoscopic therapy were recruited. Exclusion criteria were: known liver disease ; signs of cirrhosis at ultrasound (irregular liver veins and/or surface); heart insufficiency (NYHA III-VI). ARFI (Siemens S2000), ultrasound and blood examinations were performed before and in a subgroup after successful biliary drainage. RESULTS: In total, 21 patients with cholestasis were included in the study. ARFI measurements were above the cut-off for cirrhosis (1.8 m/s) in all patients with a mean of 2.91 m/s ± 0.89 m/s without a history or signs of cirrhosis . Bilirubin , γGT and AP were elevated on average to 9 .7 ± 5.3 mg/dl, 1192 ± 960 U/l and 730 ± 389 U/l. A subgroup of 10 patients was measured after successful drainage. ARFI measurements declined in all patients of that subgroup on average by 0.76 m/s at a mean time interval of 4.5 days (p < 0.001). CONCLUSION: Cholestasis significantly increases liver stiffness assessed by ARFI. Therefore, it is important to exclude profound cholestasis when using ARFI for evaluating patients for liver fibrosis . © Georg Thieme Verlag KG Stuttgart · New York.
Entities: Chemical
Disease
Species
Mesh： See more »
Substances： See more »
Year: 2014
PMID： 24824763 DOI： 10.1055/s-0034-1366057
Source DB: PubMed Journal: Ultraschall Med ISSN： 0172-4614 Impact factor: 6.548